生血丸防治化疗所致骨髓抑制32例临床观察

Clinical Observation on Shengxue Pills(生血丸) in Preventing and Treating 32 Cases of Chemotherapy-Induced Myelosuppression

目的观察生血丸对化疗所致骨髓抑制的临床疗效。方法将64例确诊为非小细胞肺癌、肠癌、胃癌、乳腺癌的肿瘤患者随机分为治疗组和对照组各32例,两组均给予常规剂量化疗方案。治疗组于化疗前7天开始口服生血丸;对照组于化疗前7天开始口服益血生胶囊,两组均以28天为1个疗程。于治疗前及治疗第7、14、21天检测两组血常规,包括白细胞(WBC)、血红蛋白(HGB)、血小板(PLT);于治疗前后检测免疫功能指标,即T细胞亚群(CD3+、CD4+、CD8+、CD4+/CD8+)、NK细胞、白细胞介素-2(IL-2)、白细胞介素-10(IL-10)、γ干扰素(INF-γ)水平,并进行临床症状积分、卡氏评分(KPS)。结果与治疗前比较,化疗第7天,对照组WBC显著下降(P<0.05);两组化疗第21天与治疗前比较,WBC均明显升高(P<0.05),治疗组高于对照组(P<0.05)。治疗后治疗组CD3+、CD4+、CD4+/CD8+较治疗前明显升高(P<0.05);对照组CD3+、NK较治疗前明显升高(P<0.05);治疗组治疗后CD4+、CD4+/CD8+水平高于对照组(P<0.05)。与治疗前比较,治疗后两组IL-2、INF-γ水平均有所上升(P<0.05)。两组临床症状积分治疗后均较治疗前降低(P<0.01);治疗后两组KPS评分均较治疗前上升(P<0.05);治疗后两组KPS评分及临床症状积分比较差异均无统计学意义(P>0.05)。结论生血丸具有保护骨髓造血功能、提高机体免疫功能、改善临床症状及提高生活质量的作用,且对提高CD4+、CD4+/CD8+水平效果优于益血生胶囊。

Objective To observe the efficacy of Shengxue Pills （ pills to promote the production of blood, 生血丸） for chemotherapy-induced myelosuppression. Methods Totally 64 cases of non-small cell lung cancer, colon cancer, stomach cancer and breast cancer were randomized into the treatment group and control group, with 32 in each. Both groups were given conventional chemotherapy. The patients in the treatment group began to taken Shengxue Pills 7 days before chemotherapy, while the patients in the control group were given Yixuesheng Capsules （ 益血丸） . One treatment course lasted for 28 days. The counts of white blood cell （ WBC ）, hemoglobin （ HGB ） and platelet （PLT） were detected before treatment and on the 7th, 14th and 21st day of treatment in both groups. The levels of CD3＋, CD4＋, CD8＋, CD4＋/CD8＋, natural killer （NK） cells, interleukin-2 （IL-2）, IL-10 and interfer- on-7 （INF-7） were detected before and after treatment. The scores of symptoms and Karnofsky performance status （KPS） were observed.